
Innovative Drug Developer

Pharmaceutical giant Novartis sees another personnel change. Yan Qiong, the current head of the oncology therapeutic area at Novartis China, is about to step down. This position will be temporarily filled by Chen Hui, the current head of retail, emerging markets, and the commercial department, who will report to the general manager.
The following is the full official announcement:

Yan Qiong once served as the head of Novartis' immunotherapy field. She has a diversified educational background with a bachelor's degree in biomedical engineering from Capital Medical University and a master's degree in computer artificial intelligence from the UK. She worked in AstraZeneca's oncology division for nine years before starting her career at Novartis in 2012.
On July 29, 2021, Novartis China underwent structural adjustments across multiple business units. Among these changes, the county-level team was transferred to the Immunology, Hepatology, and Dermatology Business Unit, and Yan Qiong, the then head of the Cardiovascular, Renal, and Metabolic Business Unit, was appointed as the head of the Immunology, Hepatology, and Dermatology Business Unit.
On June 1, 2022, the new organizational structure of Novartis Innovative Drugs China officially took effect, with Qiong Yan, former head of the Immunology Division of Novartis Pharmaceuticals China, assuming the role of Head of Immunotherapy at Novartis Innovative Drugs China. In October of the same year, Qiong Yan left Novartis to join Menarini as the Chief Executive Officer of Menarini China.
After Yan Qiong returned to Novartis, she focused on the market promotion of Novartis' key oncology product, Kayrilon (Ribociclib Succinate Tablets), as well as the growth of Jakavi and Tafinlar-Mekinist. Kayrilon is the first key product after the merger of Novartis Pharmaceuticals and Novartis Oncology. During Yan Qiong's tenure, overall performance was achieved, realizing rapid business growth and further expanding the innovative product pipeline.

Business Cooperation
130 6172 3098
zakk.cui@siqibest.com

ClickRead the Original Text Learn More